Q: What is Benlysta used for?

Benlysta is used to treat systemic lupus erythematosus and lupus nephritis .

Q: How does Benlysta work?

Mechanism of Action Benlysta is a monoclonal antibody, which is a type of protein designed to recognize and attach to a specific substance in the body. It works by binding to a protein called B-lymphocyte stimulator (BLyS). Targeting B-Cells B-cells are a type of white blood cell that play a key role in the immune system. In people with systemic lupus erythematosus (SLE) or lupus nephritis, these cells can become overactive and produce autoantibodies. These autoantibodies mistakenly attack the body's own healthy tissues, leading to inflammation and organ damage. BLyS is a protein that B-cells need to survive and mature. People with lupus often have high levels of BLyS, which allows abnormal B-cells to survive longer and continue attacking the body. Reducing Disease Activity When Benlysta attaches to BLyS, it prevents the protein from stimulating B-cells. By blocking this signal, the medication helps to: Reduce the number of abnormal B-cells in the body. Lower the production of autoantibodies that cause inflammation. Decrease the overall activity of the disease and help prevent flares. By limiting the immune system's attack on healthy tissues, Benlysta helps manage the symptoms of lupus and may reduce the risk of long-term organ damage.

Q: What are the active ingredients in Benlysta?

The active ingredient in Benlysta is belimumab .

Q: What are the side effects of Benlysta?

Common side effects of Benlysta may include: Nausea Diarrhea Fever and others. Always consult with a healthcare professional about potential side effects.

Q: What is the dosage of Benlysta and how do I take it?

Methods of Administration Benlysta is available in two forms: an intravenous (IV) infusion and a subcutaneous injection. The method used depends on the specific condition being treated and the recommendation of a healthcare provider. Intravenous Infusion When given as an infusion, the medication is delivered directly into a vein by a healthcare professional in a clinical setting. This process typically takes about one hour. The initial doses are usually given more frequently, followed by maintenance doses every few weeks. Subcutaneous Injection The injection form is typically administered once a week. It can be self-injected or given by a caregiver after receiving proper training from a healthcare provider. Common injection sites include the abdomen or the thigh. Preparation: If the medication is stored in the refrigerator, it should be allowed to reach room temperature naturally before use. Do not use external heat sources like a microwave or hot water. Site Rotation: It is important to rotate the injection site with each dose. Avoid injecting into areas where the skin is tender, bruised, red, or hard. Disposal: Used needles and syringes should be placed in a puncture-resistant sharps container immediately after use. Missed Doses If a dose of the injection is missed, it should be taken as soon as it is remembered. If it is almost time for the next scheduled dose, the missed dose should be skipped, and the regular schedule should be resumed. Do not use extra medication to make up for a missed dose. If an infusion appointment is missed, contact a healthcare provider immediately to reschedule.

Q: Is Benlysta safe during pregnancy and breastfeeding?

Pregnancy There is limited information regarding the use of Benlysta in pregnant women. Because Benlysta is a monoclonal antibody, it can cross the placenta and may affect the developing fetus. Animal studies have not shown a clear risk of harm, but human data are insufficient to determine if there is a drug-associated risk of major birth defects or miscarriage. Healthcare providers may encourage patients who become pregnant while taking Benlysta to enroll in a pregnancy registry. These registries collect information to help researchers understand the effects of the medication on pregnancy outcomes. Contraception Individuals who can become pregnant should use effective birth control during treatment with Benlysta. This should continue for at least four months after the final dose, as the medication can remain in the body for an extended period. Breastfeeding It is currently unknown whether Benlysta passes into human breast milk or if it has any effect on a nursing infant or milk production. While many antibodies are excreted in human milk, the amount absorbed by the infant is generally thought to be low. Patients should discuss the risks and benefits of breastfeeding while using this medication with their healthcare provider.

Q: What is the FDA approval status of Benlysta?

FDA Approval History Benlysta was first approved by the U.S. Food and Drug Administration (FDA) in March 2011. It was the first new drug approved for systemic lupus erythematosus (SLE) in over 50 years. The FDA later expanded its approval to include a subcutaneous injection form in 2017 and pediatric use for children aged 5 and older in 2019. Approved Indications The FDA has approved Benlysta for use in the following populations: Adults and children (5 years and older) with active, autoantibody-positive systemic lupus erythematosus (SLE) who are receiving standard therapy. Adults and children (5 years and older) with active lupus nephritis who are receiving standard therapy. Benlysta is not recommended for patients with severe active central nervous system lupus or for use in combination with other biological therapies. Safety and Monitoring There are no boxed warnings or Risk Evaluation and Mitigation Strategy (REMS) requirements for Benlysta. The FDA-approved labeling includes precautions regarding the risk of serious infections, hypersensitivity reactions, and psychiatric events such as depression or suicidal behavior. Patients are monitored for these risks as part of standard clinical practice.

Question 1

What is Benlysta?

Accepted Answer

Benlysta is a monoclonal antibody that functions as a B-lymphocyte stimulator (BLyS) protein inhibitor. It works by binding to specific proteins in the blood that are required for the survival and activity of B-cells.

By limiting the activity of these immune cells, the medication helps to decrease the production of autoantibodies that contribute to immune system overactivity. This mechanism is intended to reduce the inflammation and damage caused by certain chronic autoimmune processes.

Question 2

What is Benlysta used for?

Accepted Answer

Benlysta is used to treat systemic lupus erythematosus and lupus nephritis.

Question 3

How does Benlysta work?

Accepted Answer

Mechanism of Action

Benlysta is a monoclonal antibody, which is a type of protein designed to recognize and attach to a specific substance in the body. It works by binding to a protein called B-lymphocyte stimulator (BLyS).

Targeting B-Cells

B-cells are a type of white blood cell that play a key role in the immune system. In people with systemic lupus erythematosus (SLE) or lupus nephritis, these cells can become overactive and produce autoantibodies. These autoantibodies mistakenly attack the body's own healthy tissues, leading to inflammation and organ damage.

BLyS is a protein that B-cells need to survive and mature. People with lupus often have high levels of BLyS, which allows abnormal B-cells to survive longer and continue attacking the body.

Reducing Disease Activity

When Benlysta attaches to BLyS, it prevents the protein from stimulating B-cells. By blocking this signal, the medication helps to:

Reduce the number of abnormal B-cells in the body.
Lower the production of autoantibodies that cause inflammation.
Decrease the overall activity of the disease and help prevent flares.

By limiting the immune system's attack on healthy tissues, Benlysta helps manage the symptoms of lupus and may reduce the risk of long-term organ damage.

Question 4

What are the active ingredients in Benlysta?

Accepted Answer

The active ingredient in Benlysta is belimumab.

Question 5

What are the side effects of Benlysta?

Accepted Answer

Common side effects of Benlysta may include:

Nausea
Diarrhea
Fever
and others.

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Benlysta?

Accepted Answer

Benlysta belongs to the monoclonal antibody drug class.

Question 7

What is the dosage of Benlysta and how do I take it?

Accepted Answer

Methods of Administration

Benlysta is available in two forms: an intravenous (IV) infusion and a subcutaneous injection. The method used depends on the specific condition being treated and the recommendation of a healthcare provider.

Intravenous Infusion

When given as an infusion, the medication is delivered directly into a vein by a healthcare professional in a clinical setting. This process typically takes about one hour. The initial doses are usually given more frequently, followed by maintenance doses every few weeks.

Subcutaneous Injection

The injection form is typically administered once a week. It can be self-injected or given by a caregiver after receiving proper training from a healthcare provider. Common injection sites include the abdomen or the thigh.

Preparation: If the medication is stored in the refrigerator, it should be allowed to reach room temperature naturally before use. Do not use external heat sources like a microwave or hot water.
Site Rotation: It is important to rotate the injection site with each dose. Avoid injecting into areas where the skin is tender, bruised, red, or hard.
Disposal: Used needles and syringes should be placed in a puncture-resistant sharps container immediately after use.

Missed Doses

If a dose of the injection is missed, it should be taken as soon as it is remembered. If it is almost time for the next scheduled dose, the missed dose should be skipped, and the regular schedule should be resumed. Do not use extra medication to make up for a missed dose. If an infusion appointment is missed, contact a healthcare provider immediately to reschedule.

Question 8

Is Benlysta safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

There is limited information regarding the use of Benlysta in pregnant women. Because Benlysta is a monoclonal antibody, it can cross the placenta and may affect the developing fetus. Animal studies have not shown a clear risk of harm, but human data are insufficient to determine if there is a drug-associated risk of major birth defects or miscarriage.

Healthcare providers may encourage patients who become pregnant while taking Benlysta to enroll in a pregnancy registry. These registries collect information to help researchers understand the effects of the medication on pregnancy outcomes.

Contraception

Individuals who can become pregnant should use effective birth control during treatment with Benlysta. This should continue for at least four months after the final dose, as the medication can remain in the body for an extended period.

Breastfeeding

It is currently unknown whether Benlysta passes into human breast milk or if it has any effect on a nursing infant or milk production. While many antibodies are excreted in human milk, the amount absorbed by the infant is generally thought to be low. Patients should discuss the risks and benefits of breastfeeding while using this medication with their healthcare provider.

Question 9

What forms and strengths does Benlysta come in?

Accepted Answer

Benlysta is supplied in two primary formats depending on the method of administration:

Intravenous (IV) Infusion: This form is a powder provided in single-dose vials. A healthcare professional must reconstitute and dilute the powder before administering it into a vein over a period of about one hour.
Subcutaneous Injection: This form is a liquid solution available in single-dose prefilled autoinjectors or single-dose prefilled syringes. It is designed for injection under the skin of the stomach area or thigh.

Question 10

What is the FDA approval status of Benlysta?

Accepted Answer

FDA Approval History

Benlysta was first approved by the U.S. Food and Drug Administration (FDA) in March 2011. It was the first new drug approved for systemic lupus erythematosus (SLE) in over 50 years. The FDA later expanded its approval to include a subcutaneous injection form in 2017 and pediatric use for children aged 5 and older in 2019.

Approved Indications

The FDA has approved Benlysta for use in the following populations:

Adults and children (5 years and older) with active, autoantibody-positive systemic lupus erythematosus (SLE) who are receiving standard therapy.
Adults and children (5 years and older) with active lupus nephritis who are receiving standard therapy.

Benlysta is not recommended for patients with severe active central nervous system lupus or for use in combination with other biological therapies.

Safety and Monitoring

There are no boxed warnings or Risk Evaluation and Mitigation Strategy (REMS) requirements for Benlysta. The FDA-approved labeling includes precautions regarding the risk of serious infections, hypersensitivity reactions, and psychiatric events such as depression or suicidal behavior. Patients are monitored for these risks as part of standard clinical practice.

Question 11

What should I know about Benlysta and cost?

Accepted Answer

Several factors determine the total out-of-pocket expense for Benlysta treatment:

Administration Method: Benlysta is available as an intravenous (IV) infusion administered by a healthcare professional or as a subcutaneous injection that can be self-administered. Costs may differ between these forms.
Insurance Coverage: Most commercial insurance plans and Medicare provide coverage for Benlysta, though the specific copay or coinsurance amount depends on the individual plan's formulary.
Prior Authorization: Insurance providers often require prior authorization, meaning the doctor must prove the medication is medically necessary before the plan will cover the cost.

Because Benlysta is a specialty biologic medication with a high list price, financial support options are often available to help manage costs:

Copay Program: The manufacturer offers a copay assistance program for eligible patients with commercial (private) insurance, which can significantly reduce monthly out-of-pocket costs.
Patient Assistance: For individuals who are uninsured or underinsured, patient assistance programs may provide the medication at no cost if specific income and eligibility requirements are met.
Government Programs: Patients with Medicare, Medicaid, or other government-funded insurance are generally not eligible for manufacturer copay cards but may qualify for other forms of low-income subsidies or independent foundation support.

Benlysta is typically dispensed through a specialty pharmacy rather than a standard retail pharmacy. These pharmacies specialize in handling complex medications that require specific storage conditions, such as refrigeration, and provide additional support services for patients.

Benlysta

📋Overview

How It Works

Uses

Active Ingredients

Common Side Effects

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

📚References

Found an Error?

Find Discounts for Benlysta

Hospitals.net Disclosure